NASDAQ: BRNS - Barinthus Biotherapeutics plc

六个月盈利: -26.06%
股息率: 0.00%

促销时间表 Barinthus Biotherapeutics plc


关于公司 Barinthus Biotherapeutics plc

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

更多详情
The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

IPO date 2021-04-30
ISIN US91864C1071
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.barinthusbio.com
Цена ао 2.4
每日价格变化: 0% (1.06)
每周价格变化: -4.5% (1.11)
每月价格变化: +11.02% (0.9548)
3个月内价格变化: -10.18% (1.1801)
六个月内的价格变化: -26.06% (1.4336)
每年价格变化: -71.27% (3.69)
3年内价格变化: -88.38% (9.12)
5年内价格变化: 0% (1.06)
10年价格变化: 0% (1.06)
年初以来价格变化: -22.82% (1.3734)

低估

姓名 意义 年级
P/S 167.83 1
P/BV 0.7226 10
P/E 0 0
EV/EBITDA -0.0845 0
全部的: 5.13

效率

姓名 意义 年级
ROA, % -34.33 0
ROE, % -39.42 0
全部的: 0

股息

姓名 意义 年级
Div yield, % 0 0
DSI 0 0
全部的: 0

责任

姓名 意义 年级
Debt/EBITDA -0.1826 10
全部的: 9.4

成长冲动

姓名 意义 年级
盈利能力 Revenue, % -88.38 0
盈利能力 Ebitda, % 179.78 10
盈利能力 EPS, % 212.67 10
全部的: 8

导师 职称 支付 出生年份
Mr. William J. Enright MBA CEO & Director 969.44k 1962 (63 年)
Ms. Sarah Gilbert Co-Founder 48.98k
Mr. Adrian Hill Ph.D. Co-Founder & Scientific Advisor 61.61k
Ms. Gemma Brown CFO & Company Secretary N/A 1991 (34 年)
Dr. Nadege Pelletier Ph.D. Chief Scientific Officer 593.48k 1979 (46 年)
Mr. Graham Griffiths Chief Operating Officer 522.23k 1979 (46 年)
Ms. Elizabeth Eagling-Vose M.B.A. Head of Clinical Operations N/A
Bernie McDonald Head of IP N/A
Geoffrey Lynn Senior Vice President of Synthetic Immunotherapies N/A
Dr. Leon Hooftman M.D. Chief Medical Officer

地址: United Kingdom, Harwell OX DF, Zeus Building - 在 Google 地图中打开, 打开 Yandex 地图
网站: https://www.barinthusbio.com